Analysis of the expression pattern of the BCL11B gene and its relatives in patients with T-cell acute lymphoblastic leukemia

Journal of Hematology and Oncology

Volumn 3, Issue , 2010, Pages

  Huang, Xin ^a,b   Chen, Shaohua ^a   Shen, Qi ^a   Yang, Lijian ^a   Li, Bo ^a   Zhong, Liye ^a,b   Geng, Suxia ^b   Du, Xin ^b   Li, Yangqiu ^a,c  

^a MEDICAL COLLEGE OF JINAN UNIVERSITY   (China)

^b GUANGDONG PROVINCIAL PEOPLE'S HOSPITAL   (China)

^c JINAN UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIC AMP RESPONSIVE ELEMENT BINDING PROTEIN BINDING PROTEIN; OSTEOPONTIN; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND 10; UNCLASSIFIED DRUG; BCL11B PROTEIN, HUMAN; BCL2L1 PROTEIN, HUMAN; CREBBP PROTEIN, HUMAN; PROTEIN BCL X; REPRESSOR PROTEIN; TUMOR SUPPRESSOR PROTEIN;

ACUTE LYMPHOBLASTIC LEUKEMIA; ADOLESCENT; ADULT; ARTICLE; BCL 11B GENE; CHILD; CLINICAL ARTICLE; GENE; GENE EXPRESSION; GENE OVEREXPRESSION; GENE SEQUENCE; HUMAN; MALE; PRESCHOOL CHILD; REAL TIME POLYMERASE CHAIN REACTION; SCHOOL CHILD; BIOSYNTHESIS; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GENETICS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

ADOLESCENT; ADULT; BCL-X PROTEIN; CHILD; CREB-BINDING PROTEIN; GENE EXPRESSION; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; PRECURSOR T-CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; REPRESSOR PROTEINS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; TUMOR SUPPRESSOR PROTEINS; YOUNG ADULT;

EID: 78149494736     PISSN: None     EISSN: 17568722     Source Type: Journal    
DOI: 10.1186/1756-8722-3-44     Document Type: Article

References (27)

1. Acute lymphoblastic leukemia. GK Rivera WM Crist, Principles and Practice of Hematology. Blood, Handin RI, Stossel TP, Lux SE, 1995 743 759
2. Biology and treatment of childhood T-lineage acute lymphoblastic leukemia. FM Uckun MG Sensel L Sun PG Steinherz ME Trigg NA Heerema, Blood 1998 91 735 746 9446631
3. Receptor-Directed Therapy of T-Cell Leukemias and Lymphomas. JC Morris TA Waldmann JE Janik, J Immunotoxicol 2008 5 235 248 10.1080/15476910802129661 18569395
4. siRNA delivery systems for cancer treatment. YK Oh TG Park, Adv Drug Deliv Rev 2009 61 850 862 10.1016/j.addr.2009.04.018 19422869
5. siRNA-based approaches in cancer therapy. RS Devi, Cancer Gene Therapy 2006 13 819 829 10.1038/sj.cgt.7700931 16424918
6. Knocking down barriers: Advances in siRNA delivery. KA Whitehead R Langer DG Anderson, Nat Rev Drug Discov 2009 8 129 138 10.1038/nrd2742 19180106
7. Bcl11a is essential for normal lymphoid development. P Liu JR Keller M Ortiz L Tessarollo RA Rachel T Nakamura NA Jenkins NG Copeland, Nat Immunol 2003 4 525 532 10.1038/ni925 12717432
8. Disruption of the BCL11B gene through inv 14 q11.2q32.31 results in the expression of BCL11B-TRDC fusion transcripts and is associated with the absence of wild-type BCL11B transcripts in T-ALL. GK Przybylski WA Dik J Wanzeck P Grabarczyk S Majunke JI Martin-Subero R Siebert G Dölken WD Ludwig B Verhaaf JJ van Dongen CA Schmidt AW Langerak, Leukemia 2005 19 201 208 10.1038/sj.leu.2403619 15668700
9. Bcl11b mutations identified in murine lymphomas increase the proliferation rate of hematopoietic progenitor cells. A Karlsson A Nordigården JI Jönsson P Söderkvist, BMC Cancer 2007 7 195 10.1186/1471-2407-7-195 17941976
10. Juxtaposition of the BCL11B gene to a novel region at 17q by a t(14;17) (q32; Q21) in childhood T-Cell lymphoblastic lymphoma [abstract]. S Strehl M Konig K Spath, Blood 2007 110 101B
11. HOX11L2/TLX3 is transcriptionally activated through T-cell regulatory elements downstream of BCL11B as a result of the t(5;14) (q35;q32). XY Su V Della-Valle I Andre-Schmutz C Lemercier I Radford-Weiss P Ballerini M Lessard M Lafage-Pochitaloff F Mugneret R Berger SP Romana OA Bernard V Penard-Lacronique, Blood 2006 108 4198 4201 10.1182/blood-2006-07-032953 16926283
12. Identification of subtype-specific genomic alterations in aggressive adult T-cell leukemia/lymphoma. A Oshiro H Tagawa K Ohshima K Karube N Uike Y Tashiro A Utsunomiya M Masuda N Takasu S Nakamura Y Morishima M Seto, Blood 2006 107 4500 4507 10.1182/blood-2005-09-3801 16484591
13. Lack of Bcl11b tumor suppressor results in vulnerability to DNA replication stress and damages. K Kamimura Y Mishima M Obata, Oncogene 2007 26 5840 5850 10.1038/sj.onc.1210388 17369851
14. Regulation of mitochondrial membrane permeabilization by BCL-2 family proteins and caspases. DG Breckenridge D Xue, Curr Opin Cell Biol 2004 16 647 652 10.1016/j.ceb.2004.09.009 15530776
15. The translocation t(8;16)(p11;13) of acute myeloid leukaemia fuses a putative acetyltransferase to the CREB-binding protein. J Borrow VP Stanton Jr JM Andresen R Becher FG Behm RS Chaganti CI Civin C Disteche I Dubé AM Frischauf D Horsman F Mitelman S Volinia AE Watmore DE Housman, Nature Genet 1996 14 33 41 10.1038/ng0996-33 8782817
16. Detection of CBP rearrangements in acute myelogenous leukemia with t(8;16). RH Giles JG Dauwerse C Higgins F Petrij JW Wessels GC Beverstock H Döhner M Jotterand-Bellomo JH Falkenburg RM Slater GJ van Ommen A Hagemeijer BA van der Reijden MH Breuning, Leukemia 1997 11 2087 2096 10.1038/sj.leu.2400882 9447825
17. PI3-K/Akt-dependent activation of cAMP-response element-binding (CREB) protein in Jurkat T leukemia cells treated with TRAIL. L Caravatta S Sancilio V di Giacomo R Rana A Cataldi R Di Pietro, J Cell Physiol 2008 214 192 200 10.1002/jcp.21186 17579344
18. The Bcl-2 apoptotic switch in cancer development and therapy Bcl-2 apoptotic switch in cancer. JM Adams S Cory, Oncogene 2007 26 1324 1337 10.1038/sj.onc.1210220 17322918
19. Role of osteopontin in adhesion, migration, cell survival, and bone remodeling. T Standal M Borset A Sundan, Exp Oncol 2004 26 179 184 15494684
20. Osteopontin: role in cell signaling and cancer progression. H Rangaswami A Bulbule GC Kundu, Trends Cell Biol 2006 16 79 87 10.1016/j.tcb.2005.12.005 16406521
21. Effects of down-regulating BCL11B expression on the proliferation, apoptosis and global gene expression profiling of Molt-4 cells [Abstract]. X Huang S Chen LJ Yang SH Chen YB Zhou CA Schmidt YQ Li, Blood 2009 114 4505 10.1182/blood-2009-02-206219
22. Inhibition of BCL11B expression leads to apoptosis of malignant but not normal mature T cells. P Grabarczyk GK Przybylski M Depke U Völker J Bahr K Assmus BM Bröker R Walther CA Schmidt, Oncogene 2007 26 3797 3810 10.1038/sj.onc.1210152 17173069
23. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. KJ Livak TD Schmittgen, Methods 2001 25 402 408 10.1006/meth.2001.1262 11846609
24. Relative expression software tool (REST) for group-wise comparison and statistical analysis of relative expression results in real-time PCR. MW Pfaffl GW Horgan L Dempfle, Nucleic Acids Res 2002 30 36 10.1093/nar/30.9.e36 11972351
25. Bcl-XL disrupts death-inducing signal complex formation in plasma membrane induced by hypoxia/reoxygenation. X Wang J Zhang HP Kim, FASEB J 2004 18 1826 1833 10.1096/fj.04-2047com 15576486
26. The role of osteopontin in tumor progression and metastasis in breast cancer. LR Rodrigues JA Teixeira FL Schmitt M Paulsson H Lindmark-Mänsson, Cancer Epidemiol Biomarkers Prev 2007 16 1087 1097 10.1158/1055-9965.EPI-06-1008 17548669
27. Inhibitory action of Wnt target gene osteopontin on mitochondrial cytochrome c release determines renal ischemic resistance. JL Vĩas A Sola M Jung C Mastora E Vinuesa F Pi G Hotter, Am J Physiol Renal Physiol 2010 299 234 242 10.1152/ajprenal.00687.2009 20392802